Document:

Exhibit 10.9

 

FIRST AMENDMENT TO

LICENSE AND SUPPLY AGREEMENT

 

This First Amendment (the
 "Amendment") to that certain License and Supply Agreement, dated March 10, 2015, (the "Agreement") by
and between JOURNEY MEDICAL CORPORATION, a corporation organized and existing under the laws of Delaware ("Journey")
and BLU CARIBE, INC., a corporation organized and existing under the laws of Puerto Rico ("Blu"), is made effective
as of August 26, 2015 (the "Amendment Effective Date"). Blu and Journey are each referred to individually as a "Party"
and together as the "Parties."

 

NOW THEREFORE, in consideration
of the mutual covenants and agreements contained herein, the sufficiency of which is acknowledged by both Parties, the Parties agree as
follows:

 

		1.	Definitions. Unless otherwise defined in this Amendment, initially capitalized terms used
herein shall have the meanings given to them in the Agreement.

 

		2.	Section 5.1. Section 5.1 of the Agreement is hereby amended to add the following new Section
5.1(c):

 

(c) Upon or following Blu filing with
the FDA a Prior Approval Supplement that (i) is for the 50mg version of the Journey Product and (ii) has been pre-approved in writing
by Blu ("PAS"), Journey will pay to the FDA on behalf of Blu the respective filing fee in the amount of $[***] (the "Filing
Payment"). The Filing Payment will be creditable against Journey Revenue Share payments due to Blu under this Agreement."

 

		3.	No Other Modifications. Except as specifically set forth in this Amendment, the terms and
conditions of the Agreement shall remain in full force and effect. No waiver of the performance of any obligation under this Amendment
shall be effective unless it has been given in writing and signed by the Party giving such waiver. No provision of this Amendment may
be amended or modified other than by a written document signed by authorized representatives of each Party.

 

THIS AMENDMENT AND THE AGREEMENT AS
AMENDED BY THIS AMENDMENT SET FORTH THE ENTIRE AGREEMENT AND UNDERSTANDING OF THE PARTIES WITH RESPECT TO THE SUBJECT MATTER HEREOF, AND
SUPERCEDES ALL PRIOR DISCUSSIONS, AGREEMENTS AND WRITINGS IN RELATION THERETO.

 

		4.	Miscellaneous. This Amendment may be executed in two (2) or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment shall be governed
by and construed in accordance with the laws of the State of Delaware, without reference to any rules of conflict of laws.

 

[SIGNATURE PAGE FOLLOWS]

 

    1

     

    

  

IN WITNESS WHEREOF,
the Parties intending to be bound have caused this Amendment to be executed by their duly authorized representatives.

 

	JOURNEY MEDICAL CORPORATION	 
	 	 
	By:	/s/ Claude Maraoui	 
	Name:	Claude Maraoui	 
	Title:	President & CEO	 
	 	 
	 	 
	BLU CARIBE, INC.	 
	 	 
	By:	/s/ Bill Luster	 
	Name:	Bill Luster	 
	Title:	President	 

  

    2Exhibit 10.10 

 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY
HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]. 

 

ASSET PURCHASE AGREEMENT

 

By and between

 

JOURNEY MEDICAL CORPORATION

 

and

 

SUN PHARMACEUTICAL INDUSTRIES, INC.

 

Dated: August 31, 2018

 

     

     

    

 

ASSET PURCHASE AGREEMENT

 

THIS ASSET PURCHASE AGREEMENT
(the “Agreement”), dated August 31, 2018 (“Effective Date”), is entered into by and between Journey
Medical Corporation, a Delaware corporation having its principal place of business at 9237 Via De Ventura Suite 135, Scottsdale, AZ 85258
(the “Buyer”) and Sun Pharmaceutical Industries, Inc, a Michigan corporation, located at [***] (the “Seller”).
Buyer and Seller are referred to herein individually as a “Party” and collectively as the “Parties”.

 

WHEREAS, Seller owns and possesses
the Transferred Assets (as defined herein).

 

WHEREAS, Seller desires to
sell, transfer and assign to Buyer, and Buyer desires to purchase from Seller all of Seller’s right, title and interest in the Transferred
Assets (as defined herein) with respect to the Territory upon the terms and subject to the conditions set forth herein.

 

NOW, THEREFORE, in consideration
of the mutual covenants contained herein and intending to be legally bound hereby, the Parties hereto agree as follows:

 

ARTICLE
1

DEFINITIONS

 

As used in this Agreement,
the following terms shall have the meanings set forth below:

 

1.1             
“Action or Proceeding” means any action, suit, proceeding, arbitration, court order, inquiry, hearing, assessment
with respect to fines or penalties or litigation (whether civil, criminal, administrative, investigative or informal) commenced, brought,
conducted or heard by or before, or otherwise involving, any Governmental Authority.

 

1.2             
“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly through one or
more intermediaries, controls, or is controlled by, or is under common control with, such first Person from time to time. For purposes
of this definition, the term “control” (including the terms “controlled by” and “under common control with”)
means (a) the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such
Person, whether through ownership of voting securities, by contract relating to voting rights or corporate governance, or otherwise or
(b) the ownership, directly or indirectly, of more than 50% of the voting securities or other ownership interest of such Person (or, with
respect to a limited partnership or other similar entity, its general partner or controlling entity).

 

1.3             
 “Ancillary Agreements” means, other than this Agreement, all other agreements, certificates and documents signed
and delivered by any party in connection with this Agreement or the transactions contemplated hereby.

 

1.4             
“Assumed Liabilities” shall have the meaning set forth in Section 2.6.

 

1.5             
“Business Day” means a day other than a Saturday, Sunday, bank or other public holiday in the State of New York,
USA.

 

1.6             
“Claim Notice” shall have the meaning set forth in Section 7.3(a).

 

    1

     

    

 

1.7             
 “Closing” shall have the meaning set forth in Section 3.1.

 

1.8             
“Closing Date” shall have the meaning set forth in Section 3.1.

 

1.9         “Commercially Reasonable Efforts” shall mean the diligent, good faith efforts, consistent with general practices
and standards in the pharmaceutical industry with those used in the pharmaceutical industry of similar size and with similar resources
of Buyer as of the date hereof, taking into account all scientific, commercial and other relevant factors, would normally use to accomplish
a similar objective for its product having similar technical and regulatory factors (including safety and efficacy), similar expected
and actual time and cost to commercialize, similar commercial and profit potential, competitive landscape, a similar proprietary position
and strategic value, and that is at a similar stage in its product life cycle as the applicable Product, in each case based on existing
and reasonably anticipated future conditions. Commercially Reasonable Efforts shall be determined on a market-by-market basis for the
Product.

 

1.10         
“Consent” means any consent, approval, authorization, waiver, permit, grant, franchise, concession, agreement,
license, exemption or order of, registration, certificate, declaration or filing with, or report or notice to, any Person, including any
Governmental Authority.

 

1.11         “Disclosure Schedules” means the disclosure schedule delivered by the Seller to the Buyer simultaneously with
the execution of this Agreement and attached herewith as Schedule 1.11.

 

1.12         
“Encumbrance” means any charge, equitable interest, hypothecation, lien, mortgage, pledge, security interest
or other encumbrance of any kind known to the Seller prior to the Effective Date.

 

1.13         
“Excluded Liabilities” shall have the meaning set forth in Section 2.6.

 

1.14         
“FDA” means the United States Food and Drug Administration and any successor agency thereto.

 

1.15         
“FDA Act” means the U.S. Federal Food, Drug and Cosmetic Act, as amended, and the rules and regulations promulgated
thereunder.

 

1.16         
“GAAP” means general accounting principles in United States of America.

 

1.17         
“Governmental Authority” means any court, tribunal, governmental agency, commission, authority, department,
ministry, official or other instrumentality of any state or federal government or any country (including any political subdivision thereof)
or association of countries, including, without limitation, the FDA.

 

1.18         
“Indemnified Party” shall have the meaning set forth in Section 7.3(a).

 

1.19         
“Indemnifying Party” shall have the meaning set forth in Section 7.3(a).

 

1.20         
“Indemnity Claims” shall have the meaning set forth in Section 7.3(a).

 

    2

     

    

 

1.21         
 “Intellectual Property” means, (a) all trademarks, service marks, trade dress, logos, trade names, and corporate
names solely and exclusively related to the distribution of the Product in the Territory as listed in Schedule 1.21(a), together with
all translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications,
registrations and renewals in connection therewith; and (b) the domain name, www.exelderm.com and the digital graphics files supporting
such site.

 

1.22         
“Inventory” means all stock of Product that are solely maintained, held, or stored by or on behalf of the Seller
as on the Closing Date for the sale, distribution and commercialization in the Territory.

 

1.23         
“Inventory Amount” shall have the meaning set forth in Section 4.2.

 

1.24         
“Inventory Statement” shall have the meaning set forth in Section 4.2.

 

1.25         
“Knowledge” means (a) in the case of Seller, the actual knowledge of the applicable Persons set forth on Schedule
1.25, and (b) in the case of Buyer, the actual knowledge of the Buyer.

 

1.26         
“Laws” means any federal, state, local, foreign or multinational laws, statutes, ordinances, regulations, rules,
standards, codes, orders, writs, injunctions, decrees, arbitration awards, agency or regulatory requirements or licenses or permits of
any kind whatsoever of any Governmental Authority, all as amended from time to time

 

1.27         
“Legal Requirement” means any statute, law, ordinance, regulation, order or rule of any Governmental Authority.

 

1.28         
“Liabilities” shall mean, collectively, any debt, obligation, duty, guaranty, claim, loss, damage, deficiency,
cost, expense, fees, commitment, obligation, responsibility, or liability of any nature (including such debt, obligation, duty, liability,
or the like, that is primary or secondary, direct, absolute or contingent, or known or unknown) regardless of whether such debt, obligation,
duty, liability, or the like, would be required to be disclosed on a balance sheet, and regardless of whether such debt, obligation, duty,
liability, or the like, is immediately due and payable.

 

1.29         
“Losses” shall mean any and all losses, damages, obligations, liabilities, Taxes, fines, fees, costs, expenses,
lost profits, diminution in value, penalties, interest, awards, judgments, claims, demands, actions, suits and settlements of any kind,
including attorneys’ and consultants’ fees and expenses and other costs and expenses.

 

1.30         
“Marketing Collateral” shall mean the materials solely and exclusively related to the Product as set forth in
Schedule 1.30.

 

1.31         
“NDA” the New Drug Application (as defined in and regulated under the FDA Act), including all applications therefor,
and all amendments, modifications, supplements and updates thereto.

 

1.32         
“Net Sales” means for any period, the aggregate gross amounts invoiced by Buyer, its Affiliates or distributors
for sales of the Product in bona fide, arms- length transactions in the

 

    3

     

    

 

Territory for use in the Territory, less following
deductions allowed or accrued by using GAAP to the extent separately invoices or displayed in the invoice:

 

(a)              
credits or allowances actually granted for damaged Product, returns, rejections, withdrawals or recall of Product or failure to
supply, chargebacks, price adjustments and billing errors or on account of retroactive price reductions affecting the Product;

 

(b)              
governmental rebates, patient vouchers or coupons granted to managed health care organizations; pharmacy benefit managers; federal,
state/provincial, local and other governments, their agencies and purchasers and reimbursers;

 

(c)              
normal and customary trade, cash and quantity discounts, allowances and credits; and

 

(d)              
sales taxes, VAT and other taxes and duties applied to the sale of Product to the extent included in the gross amount invoiced.

 

1.33         
“Notice Period” shall have the meaning set forth in Section 7.3(b).

 

1.34         
“Permitted Encumbrance” means (i) any Encumbrance for Taxes, assessments and other governmental charges that
are not yet due and payable, (ii) with respect to licenses, permits or contracts, any restrictions, obligations, limitations or other
Encumbrances contained in such license, permit or contract or existing at Law or under the regulatory regime pursuant to which such permit
or license is granted that do not materially impair the current use of the Product, or (iii) with respect to the NDA, any restrictions,
obligations, limitations or other Encumbrances contained in such NDA or existing at Law or under the regulatory regime pursuant to which
such NDA is granted that do not materially impair the current use of the Product.

 

1.35         
“Person” means any individual, corporation, general or limited partnership, limited liability company, joint
venture, estate, trust, association, organization, or other entity or Governmental Authority.

 

1.36         
“Product” means Exelderm (Cream & Solution) 1% sulconazole nitrate.

 

1.37         
“Purchase Price” shall have the meaning set forth in Section 4.1.

 

1.38         
“Royalty” or “Royalties” shall have the meaning set forth in Section 4.3.

 

1.39         
“Royalty Term” means the time period commencing on the Effective Date and ending on December 1st, 2023 during
which the Royalty is payable by the Buyer to the Seller.

 

1.40         
“Tax” or “Taxes” means any taxes or similar assessments of any kind whatsoever including,
but not limited to income, franchise, trade, capital, withholding, payroll, unemployment insurance, social security, gross receipts, sales
and use, value added, excise, real property and personal property taxes, together with all interest, penalties and additions imposed with
respect to any such taxes.

 

    4

     

    

 

1.41         
 “Territory” means the United States of America and all of its territories and possessions.

 

1.42         
“Third Party” means any Person other than a Party or any of their respective Affiliates.

 

1.43         
“Transferred Assets” shall have the meaning set forth in Section 2.1.

 

1.44         
“Upfront Payment” shall have the meaning set forth in Section 4.1.

 

ARTICLE
2

PURCHASE AND SALE OF THE TRANSFERRED ASSETS

 

2.1             
Transfer of Assets. Upon the terms and subject to the conditions set forth herein, Seller hereby sells, conveys, transfers,
assigns and delivers to Buyer, and Buyer hereby purchases from Seller all of Seller’s right, title and interest in and to the following
assets with respect to the Territory to the extent existing and controlled by the Seller (collectively, the “Transferred Assets”),
free and clear of all Encumbrances (except Permitted Encumbrances):

 

(a)     
the Product NDA;

 

(b)     
the Inventory; and

 

(c)     
all Intellectual Property related to the Product.

 

2.2             
The Parties hereby agree and acknowledge that the Product NDA and the Intellectual Property related to the Product shall be transferred
by the Seller to the Buyer on the Closing Date and the Inventory shall be transferred by the Seller to the Buyer in accordance with Section
4.2 below.

 

2.3             
License to Marketing Collaterals. Solely to the extent necessary for Buyer to market the Product in the Territory, Seller
hereby grants to Buyer a limited, non-exclusive, non-transferable and royalty free license to Seller’s rights in the Marketing Collaterals.
Upon the terms and subject to the conditions set forth herein, after the Closing, Seller shall promptly deliver to Buyer the Marketing
Collaterals. For the avoidance of doubt, nothing herein shall be construed as a grant or license of any rights to any Sun trademark, service
mark, trade dress, logo, trade name or corporate name similar or related thereto other than those specifically set forth in Schedule 1.21(a).

 

2.4             
The Buyer acknowledges and agrees that Seller may retain for archival purposes and for purposes of complying with the applicable
Laws and for legal and regulatory purposes as sellers of pharmaceutical products, one copy of all or any part of the documentation that
Seller delivers to the Buyer pursuant to this Section 2.1.

 

2.5              Other
than the Transferred Assets set forth in Section 2.1, the Buyer expressly understands and agrees that it is not purchasing or
acquiring, and the Seller is not selling or assigning, any other assets or properties of the Company not specifically related to the
Product, including but not limited to Seller’s trademarks, trade dress, logos, corporate designs, and the like that are
incorporated in the Marketing Collateral and in the digital graphics files forming part of the Intellectual Property, and all such
other assets and properties shall be excluded from the Transferred Assets.

 

    5

     

    

 

2.6             
Liability. From and after the Closing Date, Buyer shall assume, be responsible for and pay, perform and discharge when due,
and, if necessary, reimburse Seller for all matters and Liabilities (including intellectual property infringement or misappropriation
claims or actions or any other claims or actions brought by any Third Party) within the Territory arising out of or relating to the Product
and the Transferred Assets for the period after the Closing Date (“Assumed Liabilities”). For avoidance of doubt, with
respect to the Inventory, the Buyer shall assume the Assumed Liabilities from and after the date of transfer of Inventory under Section
4.2. It is hereby clarified that Buyer shall not assume and be responsible for the Liabilities arising out of or in connection with the
use and ownership of the Transferred Assets which have resulted from any acts or omissions of the Seller for the period prior to the Closing
Date (and with respect to the Inventory, prior to the date of transfer of the Inventory under Section 4.2) (“Excluded Liabilities”).

 

ARTICLE
3

CLOSING & CONDITIONS PRECEDENT

 

3.1             
Closing. The consummation of the purchase and sale of the Transferred Assets contemplated hereby (the “Closing”)
will take place on the date of receipt of the Upfront Payment by the Seller pursuant to Section 4.1(i) or, if all the conditions set forth
in Sections 3.2(a) and 3.2(b) are not then satisfied or waived, the first such Business Day thereafter on which they are waived or satisfied,
and “Closing Date” shall mean the date upon which Closing occurs.

 

3.2             
Conditions to Closing.

 

(a)              
Conditions to the Seller’s Obligations. The obligation of the Seller to consummate the transactions contemplated by
this Agreement at Closing is subject to the fulfillment of each of the following conditions (any or all of which may be waived in writing
in whole or in part by the Seller):

 

(i)                
Representations. The representations and warranties of Buyer made in Section 5 of this Agreement shall be true and correct
as of the Closing Date. Buyer shall have performed or complied in all material respects with all obligations and covenants required by
this Agreement to be performed or complied with by Buyer by the time of the Closing. Buyer shall have delivered to Seller a certificate
dated the Closing Date and signed by an authorized officer of Buyer to the effect that the conditions specified in this Section 3.2(a)
are satisfied.

 

(ii)             
Consents. The Buyer shall have received all Consents as required in order to assign to the Buyer all rights of the Seller
to the Transferred Assets; and

 

(iii)           
No Order. There shall not be in effect on the Closing Date any judgment, order, decree, ruling or charge restraining, enjoining
or otherwise prohibiting or making illegal the consummation of the transactions contemplated by this Agreement.

 

(b)               Conditions
to the Buyer’s Obligations. The obligation of the Buyer to consummate the transactions contemplated by this Agreement at
Closing is subject to the fulfillment of each of the following conditions (any or all of which may be waived in writing in whole or
in part by the Buyer):

 

    6

     

    

 

(i)                
Representations. The representations and warranties of Seller made in Section 5 of this Agreement shall be true and correct
as of the Closing Date. Seller shall have performed or complied in all material respects with all obligations and covenants required by
this Agreement to be performed or complied with by Seller by the time of the Closing. Seller shall have delivered to Buyer a certificate
dated the Closing Date and signed by an authorized officer of Seller to the effect that the conditions specified in this Section 3.2(b)
are satisfied.

 

(ii)             
Consents. The Seller shall have received all Consents as required in order to assign to the Buyer all rights of the Seller
to the Transferred Assets; and

 

(iii)           
No Order. There shall not be in effect on the Closing Date any judgment, order, decree, ruling or charge restraining, enjoining
or otherwise prohibiting or making illegal the consummation of the transactions contemplated by this Agreement.

 

3.3             
Closing Deliverables. At the Closing, the following shall be delivered:

 

(a)              
Buyer shall deliver to the Seller

 

(i)                
by wire transfer to a bank account designated in writing by Seller in US Dollars, immediately available funds in an amount equal
to the sum of the Upfront Payment; and

 

(ii)             
the certificate required to be delivered by Buyer under Section 3.2(a) duly executed by an authorized officer of Buyer.

 

(b)              
Seller shall deliver to the Buyer the certificate required to be delivered by Seller under Section 3.2(b) duly executed by an authorized
officer of Seller.

 

ARTICLE
4

PRICE & TERMS

 

4.1             
Purchase Price. As consideration for the Transferred Assets, Buyer shall pay to the Seller a non-refundable and non-creditable
payment of: (i) One Million and Two Hundred Thousand U.S. Dollars (U.S. $1,200,000) within sixty (60) days from the Effective Date (“Upfront
Payment”), (ii) the one-time milestone payment of Four Hundred Thousand U.S. Dollars (U.S. $400,000) within forty-five (45)
days following the achievement of the Net Sales of the Product for the calendar year being equal to or more than [***] U.S. Dollars (U.S.
$[***]); (iii) Inventory Amount as set forth in Section 4.2 below and (iii) Royalty, as set forth in Section 4.3 below (collectively,
with (i), (ii) and (iii) “Purchase Price”). The Buyer will pay the Purchase Price to the Company by wire transfer of
federal funds pursuant to written instructions delivered by the Seller to the Buyer.

 

    7

     

    

 

4.2              Inventory.
Seller shall prepare a statement for the Inventory it will possess on the Effective Date (“Inventory Statement”)
and provide such statement to the Buyer at least two (2) Business Days prior to the Effective Date. In consideration of the Seller
transferring the Inventory to the Buyer, Buyer shall pay to Seller an amount equivalent to the value of the total quantity of
Inventory mentioned in the Inventory Statement (i.e. USD per unit multiplied by total quantity of the Inventory) (“Inventory
Amount”). Buyer shall pay the Inventory Amount within ten (10) Business Days from the date of receipt of the Inventory
Statement. For clarity, Seller is not required to invoice Buyer for the payment of the Inventory Amount. Seller shall deliver the
Inventory as per Ex-Works (Incoterms 2010) Cranbury, New Jersey. Parties hereby agree and acknowledge that the Inventory will be
sold by Buyer with the existing label, however Buyer shall make commercially reasonable efforts to change the labelling as soon as
practicable. Seller shall reasonably assist the Buyer in handling any customer complaints/queries. Notwithstanding anything
contained herein, Buyer hereby agrees and acknowledges that it shall be solely responsible and liable for any and all claims or
actions arising out of or in connection with the handling, storing, marketing, promoting, distributing and selling of the Inventory.
Seller shall make the Inventory available to Buyer within two (2) Business Days following the Effective Date.

 

4.3             
Royalty. During the Royalty Term, the Buyer shall pay to Seller quarterly a royalty of [***]% of the Net Sales of the Product
in the Territory (the “Royalty”), payable within forty-five (45) days following the end of the applicable calendar
quarter. In the event the Net Sales of the Product is equal to or more than [***] U.S. Dollars (U.S. $[***]) in a fiscal year, thereafter
the Royalty shall become [***]% of Net Sales. The Buyer agrees to use Commercially Reasonable Efforts to commercialize the Product in
a manner which will generate maximum Net Sales in the Territory.

 

4.4             
Audit Right. Upon not less than five (5) Business Days’ written notice, Seller shall have the right to audit the books
and records of Buyer to the extent relating to Net Sales for the purposes of determining the correctness of Buyer’s computation
and payment of the Royalty. Such audit shall be conducted during normal business hours by an accountant selected by Seller. All costs
and expenses for conducting the audit shall be borne by the Seller, except that if the audit report shows that the Royalties were underpaid
or overpaid by more than two percent (2%), then all costs and expenses for conducting the audit shall be borne by Buyer. Payment of any
underpaid or overpaid Royalties, along with the costs and expenses for conducting the audit, shall be paid with or deducted from the immediately
following Royalty payment, as applicable. The right to audit under this Section by the Seller shall survive termination or expiration
of this Agreement by a period of one (1) year therefrom.

 

4.5             
Taxes and Fees. Buyer shall be responsible for and pay all Taxes imposed in connection with the transactions provided for
in this Agreement (excluding any income tax and capital gains tax on Seller), including without limitation sales taxes, value added taxes,
transfer taxes and recording fees, if any, imposed upon the transfer of the Transferred Assets, and any withholding taxes.

 

4.6             
Late Payment. The Company shall be entitled to charge [***]% interest per annum on any amounts overdue, from the due date
for payment until receipt by the Company of the full amount, without prejudice to any other right or remedy of the Company.

 

    8

     

    

 

ARTICLE
5

REPRESENTATIONS AND WARRANTIES

 

5.1             
Seller’s Warranties. Except as set forth on the Disclosure Schedule, as on the Effective Date, Seller represents and
warrants to Buyer as follows:

 

(a)              
Organization and Authority. Seller is validly existing and in good standing under the applicable Laws, with full power and
authority to execute and deliver this Agreement and to perform its obligations hereunder. This Agreement has been, and upon execution
of each of the Ancillary Agreements, such Ancillary Agreements will have been, duly and validly authorized, executed and delivered by,
and constitute the legal, valid and binding obligations of Seller enforceable in accordance with their terms.

 

(b)              
Title. Seller owns and has good and valid title to the Transferred Assets, free and clear of all Encumbrances. There are
no adverse claims of ownership to the Transferred Assets and, to the Seller’s Knowledge, Seller has not received written notice
that any individual or entity has asserted a claim of ownership or right of possession or use in or to any of the Transferred Assets.
At Closing, Buyer will acquire from Seller good and valid title to the Transferred Assets.

 

(c)              
Litigation; Legal Compliance.

 

(i)                
There is no material Action or Proceeding pending or, to Seller’s Knowledge, threatened, with respect to the Transferred
Assets, that affects or, if successful, would affect the validity of this Agreement or any action taken or to be taken by the Seller in
connection herewith, or which individually or in the aggregate, would materially impair the ability of Seller to perform its obligations
hereunder or to consummate the transactions contemplated by this Agreement or the Ancillary Agreements.

 

(ii)             
Neither Seller nor any officer, employee, agent, contractor or distributor of Seller has committed or been convicted of any crime
or engaged in any conduct for which debarment is mandated by 21 U.S.C. § 335a(a) or any similar law or authorized by 21 U.S.C. §
335a(b) or any similar applicable law. Neither Seller nor any officer, employee, agent, contractor or distributor of Seller has been convicted
of any crime or engaged in any conduct for which such person could be excluded from participating in federal health care programs under
Section 1128 of the Social Security Act of 1935, as amended, or any similar law. No claims, actions, proceedings or investigations that
could reasonably be expected to result in a debarment or exclusion are pending or threatened against Seller or any of its directors, officers,
employees or agents. Seller has never been: (i) debarred or (ii) convicted of a crime for which a person can be debarred under Section
306(a) of the Generic Drug Enforcement Act of 1992 (Section 306 (a) or (b)), and Seller has never been and, to Seller’s Knowledge,
none of its employees, Affiliates or agents has ever been: (i) threatened to be debarred or (ii) indicted for a crime or otherwise engaged
in conduct for which a person can be debarred, under Section 306(a) or (b) of the Generic Drug Enforcement Act of 1992.

 

    9

     

    

 

(iii)           
 Seller has provided to Buyer copies of all written communications to or from any Governmental Authority and associated with the
Product, including, without limitation, any written communication to or from the FDA.

 

(iv)            
The Seller possesses all material registrations, rights of reference, approvals, licenses, consents, agreements, permits and other
authorizations from Governmental Authorities, required by applicable provisions of Laws.

 

(d)              
No Conflicts. Neither the execution and the delivery of this Agreement or the Ancillary Agreements, nor the consummation
of the transactions contemplated hereby and thereby, will (i) violate any material Legal Requirement to which Seller is, or its assets
or properties are, subject, (ii) contravene, conflict with or result in a breach or violation of any provision of the charter or bylaws
of Seller.

 

(e)              
Brokers and Finders. Seller has not employed any broker, finder, consultant or intermediary in connection with the transactions
contemplated by this Agreement who would be entitled to a broker’s, finder’s or similar fee or commission in connection therewith
or upon the consummation thereof.

 

(f)               
Inventory. The Inventory is (a) free from any material defect or deficiency, (b) is in good and usable condition for sale
and (c) meets in all material respects all of the applicable requirements and specifications.

 

(g)              
Intellectual Property.

 

(i)                
Seller exclusively owns the Intellectual Property free and clear of all Liens. The Intellectual Property will, immediately subsequent
to the Closing, be transferred to, and controlled by Buyer on substantially the same terms with which Seller, immediately prior to the
Closing, owned and controlled such Intellectual Property. To Seller’s Knowledge, (i) Seller has not and is not infringing, misappropriating
or otherwise violating (including with respect to the discovery, development, clinical testing, manufacture, distribution, advertising,
use, exploitation or sale by Seller of the Product) the rights of any other Person with regard to Seller’s possession or use of
any Intellectual Property for its sale of the Product as presently conducted. To Seller’s Knowledge, no other Person has or is infringing,
misappropriating or otherwise violating the Intellectual Property. No claims against Seller are pending or, to Seller’s Knowledge,
threatened with regard to (i) the control or use of any of the Intellectual Property; or (ii) the validity or enforceability of any Intellectual
Property.

 

(ii)             
Schedule 1.21(a) sets forth, as of the date hereof, a complete and accurate list of all Intellectual Property owned by Seller
related to the Product that is being transferred to Buyer. To Seller’s Knowledge, all Intellectual Property owned by Seller that
is related to the Product has been duly registered or filed with or issued by each appropriate Governmental Authority in the jurisdiction
indicated in Schedule 1.21(a), all related necessary affidavits of continuing use have been (or, with respect to licenses, to Seller’s
Knowledge have been) timely filed, and all related necessary maintenance fees have been (or, with respect to licenses, to Seller’s
Knowledge have been) timely paid to continue all such rights in effect.

 

    10

     

    

 

(iii)           
 No Other Representation or Warranties. Except for the representations and warranties contained in this Section 5.1, Seller
makes no other express or implied warranty, and Seller hereby disclaims any such warranty or any representation whether by Seller or its
respective officers, directors, employees, agents or representatives or any other Person, as to the condition (financial or otherwise),
value or quality of the Product or the Transferred Assets, notwithstanding the delivery or disclosure to Buyer or any of its officers,
directors, employees, agents or representatives or any other Person of any documentation or other information by Seller or any of its
officers, directors, employees, agents or representatives or any other Person with respect to any one or more of the foregoing.

 

5.2             
Buyer’s Warranties. Buyer hereby represents and warrants to Seller, as of the date hereof and as of the Closing Date,
as follows:

 

(a)              
Organization and Authority of Buyer. Buyer is validly existing and is in good standing under the Applicable Laws of the
State of Delaware, with full power and authority to enter into this Agreement and perform its obligations hereunder. This Agreement has
been, and upon execution of each of the Ancillary Agreements, such Ancillary Agreements will have been duly and validly authorized, executed
and delivered by, and constitute the legal, valid and binding obligations of Buyer, enforceable in accordance with their respective terms.

 

(b)              
Litigation. There are no material Actions or Proceedings pending, or to Buyer’s Knowledge, threatened, that questions
the validity of this Agreement or any action taken or to be taken by the Buyer in connection herewith, or which individually or in the
aggregate, would materially impair the ability of Buyer to perform its obligations hereunder or to consummate the transactions contemplated
by this Agreement or the Ancillary Agreements.

 

(c)              
The Buyer possesses all material registrations, rights of reference, approvals, licenses, consents, agreements, permits and other
authorizations from Governmental Authorities, required by applicable provisions of Laws.

 

(d)              
The Buyer has and will have at Closing cash available sufficient to enable it to consummate the transactions contemplated by this
Agreement.

 

(e)              
No Conflicts. Neither the execution and the delivery of this Agreement nor the Ancillary Agreements, nor the consummation
of the transactions contemplated hereby and thereby, will (i) violate any material Legal Requirement to which Buyer is, or its assets
or properties are, subject, (ii) contravene, conflict with or result in a breach or violation of any provision of the charter or bylaws
of Buyer, or (iii) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create in any party
the right to accelerate, terminate, modify, or cancel, or require any notice under any agreement, contract, lease, license, instrument,
or other arrangement to which Buyer is a party or by which it is bound or to which any of its assets is subject. Buyer does not need to
give any material notice to, make any filing with, or obtain any authorization, consent, or approval of any Governmental Authority or
any other Person in order to consummate the transactions contemplated by this Agreement or the Ancillary Agreements. There is no proceeding
pending or, to the Knowledge of Buyer, threatened against Buyer that challenges, or may have the effect of preventing, delaying, making
illegal or otherwise interfering with the transactions contemplated by this Agreement or the Ancillary Agreements.

 

    11

     

    

 

(f)               
 Independent Investigation. The Buyer has conducted its own independent investigation, due diligence, review and analysis
of the business, operations, assets (including Contracts), liabilities, results of operations, financial condition, software, technology
and prospects of the business related to the Product, which investigation, review and analysis were undertaken by the Buyer and its Affiliates
and representatives.

 

(g)              
Brokers and Finders. Buyer has not employed any broker, finder, consultant or intermediary in connection with the transactions
contemplated by this Agreement who would be entitled to a broker’s, finder’s or similar fee or commission in connection therewith
or upon the consummation thereof.

 

5.3             
Non-Reliance. The Buyer agrees and acknowledges that the Buyer has relied solely on the representations and warranties set
forth in Section 5.1 and except for the representations and warranties expressly set forth in Section 5.1, as modified by the Disclosure
Schedule and any certificate delivered by or on behalf the Seller hereunder, neither the Seller nor any of its shareholders, trustees,
Affiliates or representatives or any other Person, has made or is making any other representations or warranties, promises, covenants,
agreements or guaranties, statutory, common law or otherwise, of any nature, oral or written, past, present or future, including any other
representations or warranties, express or implied, with respect to, and the Buyer have not relied upon, the accuracy or completeness of
any other information, provided, or made available by, the Seller or any of its representatives, with respect to, or in connection with,
the negotiation, execution or delivery of this Agreement or the transactions contemplated hereby.

 

ARTICLE
6

COVENANTS

 

6.1             
Obligations of the Parties Prior to Closing. Seller will not prior to the Closing Date (a) incur any material liability
outside the ordinary course of business with respect to the Transferred Assets, or (b) create any Encumbrance on any of the Transferred
Assets.

 

6.2             
Non-Competition. The Parties hereto agree and acknowledge that the provisions of this Agreement shall not be construed
to limit or restrict in any manner the rights of Seller or any of its Affiliates to develop, manufacture, use, sell or commercialize
in any manner the Product in a generic or other formulation, either in the Territory or outside of the Territory; provided, however,
that for a period of five (5) years commencing on the Closing Date, Seller shall not manufacture or commercialize any product containing
the same active ingredient and in the same dosage and form as that of the Product in the Territory.

 

6.3             
Use of the Transferred Assets. The Buyer agrees and acknowledges that Seller is not assigning, licensing or conveying any
rights to the Buyer outside the Territory.

 

6.4             
Standards of Quality. The Buyer agrees to comply with applicable Laws and regulations in the Territory in the marketing,
sale, and distribution of Product.

 

6.5             
Reasonable Efforts of the Parties. Seller and Buyer shall each use its respective Commercially Reasonable Efforts to cause
all of the conditions to the obligations of the other to consummate the transactions contemplated hereby to be met as soon as practicable
after the date of this Agreement and to do, or cause to be done,
all things necessary to consummate the transactions contemplated hereby.

 

    12

     

    

 

6.6             
Registrations and Filings. (a) Without prejudice to applicable Legal Requirement in the Territory that may exclude this
possibility, from and after the Closing, Buyer shall take the lead in coordinating the NDA transfers. Buyer shall file, or shall cause
its Affiliate or designee to file, or, if required by applicable Legal Requirement, Seller, its Affiliate or designee shall file, applications
for the transfer of the NDA in the Territory. (b) For the avoidance of doubt, Seller does not warrant and shall not be responsible for
the successful transfer, maintenance or renewal of the NDA after the Closing Date and shall not be obligated to launch the Product in
the Territory where it has not been launched before Closing.

 

6.7             
Prescription Drug User Fee Act. Following the Effective Date, Buyer shall assume and have responsibility for fees or charges
associated with the Product due and payable to the FDA after the Effective Date pursuant to the Prescription Drug User Fee Act, and any
reauthorization thereto. Seller shall retain full responsibility and liability for all fees or charges due and payable to the FDA on or
prior to the Effective Date.

 

6.8             
Confidentiality.

 

(a)              
Seller undertakes with Buyer, and Buyer undertakes with Seller to keep confidential (except as expressly provided in this Agreement)
at all times after the date of this Agreement, and not directly or indirectly reveal, disclose or use for its own or any other purposes,
any confidential information received or obtained as a result of entering into or performing, or supplied by or on behalf of a Party in
the negotiations leading to, this Agreement and which relates to: (i) the negotiations relating to this Agreement; or (ii) the subject
matter and/or provisions of this Agreement, subject to Section 6.8(b) below.

 

(b)              
The prohibition in Section 6.8(a) does not apply if: (i) the information was in the public domain before it was furnished to the
relevant Party or, after it was furnished to that Party, entered the public domain otherwise than as a result of a breach by that Party
of this Section 6.8 or any written or confidentiality agreement under which such Party is bound; (ii) disclosure is necessary in order
to comply with applicable legislation, regulatory requirements, legal process, or stock exchange rules, provided that any such information
disclosable pursuant to this Section 6.8(b) shall be disclosed only to the extent required by Legal Requirements and (unless such consultation
is prohibited by Legal Requirements or is not reasonably practicable) only after consultation with Buyer or Seller (as the case may be)
or (iii) Buyer is contemplating the sale, assignment, conveyance or other transfer to a Third Party of all or substantially all of its
rights, title and interest in and to the Product, provided that Buyer shall have entered into a confidentiality agreement with such Third
Party no less restrictive than this Section 6.8.

 

6.9             
Further Assurances. Seller and Buyer, agree that subsequent to the Closing Date, at the request of the other Party, they
will execute and deliver, or cause to be delivered, to the other Party, such further instruments and take such other action as may be
reasonably necessary to carry out the transactions contemplated by this Agreement.

 

    13

     

    

 

6.10         
 Costs and Expenses. Except as otherwise expressly provided herein, the Parties shall bear their own respective expenses
(including, but not limited to, all compensation and expenses of counsel, financial advisors, consultants and independent accountants)
incurred in connection with the preparation and execution of this Agreement and consummation of the transactions contemplated hereby,
including assistance reasonably requested in consummating such transactions.

 

ARTICLE
7

INDEMNIFICATION AND INSURANCE

 

7.1             
Indemnification by Seller. From and after the Closing Date, Seller shall defend, indemnify and hold harmless Buyer, its
Affiliates, officers, directors, employees, and agents, against and in respect of any and all Losses, resulting or arising from or otherwise
relating to:

 

(a)              
any breach by Seller of any covenant, representation or warranty of Seller contained in this Agreement or any Ancillary Agreements;

 

(b)              
any Liabilities resulting from the acts and omissions of the Seller prior to the Closing Date.

 

7.2             
Indemnification by Buyer. From and after the Closing Date, Buyer shall indemnify and hold harmless Seller, its Affiliates,
officers, directors, employees, and agents, against and in respect of any and all Losses resulting or arising from or otherwise relating
to:

 

(a)              
any breach by Buyer of any covenant, representation or warranty contained in this Agreement or any Ancillary Agreements;

 

(b)              
Any Assumed Liabilities;

 

(c)              
use of the Marketing Collateral(s) by the Buyer after the Closing Date; and

 

(d)              
any negligent or intentional act committed by the Buyer or its employees or agents that caused injury to a person or damage to
property, or failed to comply with any applicable law, statute, regulation or ordinance.

 

7.3             
Method of Asserting Claims.

 

(a)              
All claims for indemnification (“Indemnity Claims”) by any indemnified Party or a Party with respect to any
other claim under or with respect to this Agreement or any Ancillary Agreements (the “Indemnified Party”) hereunder
shall be asserted and resolved as set forth in this Section 7.3. In the event that any written claim or demand for which a Party (the
 “Indemnifying Party”) would be liable to any Indemnified Party hereunder is asserted against or sought to be collected
from any Indemnified Party by a Third Party, such Indemnified Party shall promptly, but in no event more than ten (10) days following
such Indemnified Party’s receipt of such claim or demand, notify the Indemnifying Party of such claim or demand and the amount or
the estimated amount thereof to the extent then feasible (the “Claim Notice”). All indemnity claims by any Indemnified
Party that do not involve Third Party claims shall be communicated via a Claim Notice to the other Party promptly following discovery
of such claim.

 

    14

     

    

 

(b)              
 The Indemnifying Party shall have fifteen (15) days from the delivery or mailing of the Claim Notice (the “Notice Period”)
to notify the Indemnified Party whether or not it desires to defend the Indemnified Party against such claim or demand. An election to
assume the defense of such claim or demand shall not be deemed to be an admission that the Indemnifying Party is liable to the Indemnified
Party in respect of such claim or demand. All costs and expenses incurred by the Indemnifying Party in defending such claim or demand
shall be a liability of, and shall be paid by, the Indemnifying Party; provided, however, that the amount of such expenses
shall be a liability of the Indemnifying Party hereunder, subject to the limitations set forth in this Article 8. In the event, however,
that the Indemnifying Party declines or fails to assume the defense of the claim within such fifteen (15)-day period, the Indemnified
Party may assume the defense thereof and the reasonable fees and disbursements of counsel for the Indemnified Party shall be deemed Losses
hereunder, subject to the limitations set forth in this Article 8.

 

(c)              
In the event that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold the Indemnified
Party harmless from and against any Third Party claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all costs
and expenses (including without limitation, attorney’s fees and court costs) actually incurred by the Indemnifying Party in its
defense of the Third Party claim. In the event that the Indemnifying Party notifies the Indemnified Party within the Notice Period that
it desires to defend the Indemnified Party against such claim or demand, the Indemnifying Party shall have the right to defend the Indemnified
Party by appropriate proceedings. If any Indemnified Party desires to participate in, but not control, any such defense or settlement,
it may do so at its sole cost and expense.

 

(d)              
The Indemnified Party shall not settle a claim or demand without the prior written consent of the Indemnifying Party, which shall
not be unreasonably withheld, conditioned or delayed. The Indemnifying Party may settle any claim or demand for monetary damages; it being
understood that the Indemnifying Party shall not, without the prior written consent of the Indemnified Party (which shall not be unreasonably
withheld, conditioned or delayed) settle, compromise or offer to settle or compromise any such claim or demand on a basis which would
result in the imposition of a consent order, injunction or decree that would substantially restrict the future activity or conduct of
the Indemnified Party or any subsidiary or Affiliate thereof.

 

(e)              
To the extent the Indemnifying Party shall control or participate in the defense or settlement of any Third Party claim or demand,
the Indemnified Party will give the Indemnifying Party and its counsel access to, during normal business hours, the relevant business
records and other documents, and shall permit them to consult with the employees and counsel of the Indemnified Party.

 

(f)               
The controlling party, in either case, shall select counsel, contractors, experts and consultants of recognized standing and competence,
shall take reasonable steps necessary in the investigation, defense or settlement thereof, and shall diligently and promptly pursue the
resolution thereof.

 

(g)               Any
notice of a claim by reason of any of the warranties or covenants contained in this Agreement shall state specifically the warranty
or covenant with respect to which the claim is made, the facts giving rise to an alleged basis for the claim, and the amount of the
liability asserted against the Indemnifying Party by reason of the claim.

 

    15

     

    

 

7.4             
Survival. The covenants and agreements of the Parties shall survive without limitation as to time, and the period during
which a claim for indemnification may be asserted in connection therewith shall continue for the applicable statute of limitations.

 

7.5             
DAMAGES LIMITATION. NOTWITHSTANDING ANYTHING TO THE CONTRARY ELSEWHERE IN THIS AGREEMENT OR ANY ANCILLARY AGREEMENT, NO
PARTY, DIRECTOR, OFFICER, EMPLOYEE, AFFILIATE OR ADVISOR OF ANY OF THE FOREGOING, SHALL, IN ANY EVENT, BE LIABLE TO ANY OTHER PERSON,
EITHER IN CONTRACT, TORT OR OTHERWISE, FOR ANY SPECIAL, INDIRECT, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES OR ANY DAMAGES ASSOCIATED
WITH ANY LOST PROFITS OR LOST OPPORTUNITIES OF SUCH OTHER PERSON (INCLUDING LOSS OF FUTURE REVENUE, INCOME OR PROFITS, DIMINUTION OF VALUE
OR LOSS OF BUSINESS REPUTATION) RELATING TO THE BREACH OR ALLEGED BREACH OF THIS AGREEMENT, WHETHER OR NOT THE POSSIBILITY OF SUCH DAMAGES
HAS BEEN DISCLOSED TO THE OTHER PARTY IN ADVANCE OR COULD HAVE BEEN REASONABLY FORESEEN BY SUCH OTHER PARTY.

 

7.6             
Limitation of Liability. Notwithstanding the foregoing, except for actions grounded in fraud, the maximum amount of indemnifiable
Losses which may be recovered cumulatively from the Seller arising out of or resulting from the causes set forth in Section 7.1 shall
be an amount equal to [***].

 

7.7             
Cooperation. The Parties shall cooperate with each other with respect to resolving any claim or liability with respect to
which one Party is obligated to indemnify another Party hereunder, including by making Commercially Reasonably Efforts to mitigate or
resolve any such claim or liability.

 

7.8             
Manufacturing. Seller shall introduce Buyer to the current manufacturer of the Product, and shall reasonably cooperate with
Buyer with respect to transitioning manufacturing services to Buyer. Seller shall not manufacture the Product following the date hereof,
including any orders of Product placed prior to the date hereof.

 

ARTICLE
8

MISCELLANEOUS

 

8.1             
Notices. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have
been duly given (a) upon delivery by personal delivery, (b) upon delivery by a nationally-recognized overnight courier service, or (c)
three days after mailing, if mailed, certified or registered mail (return receipt requested), postage prepaid, each to the other Party
at the following address (or at such other address as shall be given in writing by any Party to the other in accordance with these provisions):

 

    16

     

    

 

If to the Buyer, to:

 

Journey Medical Corporation

9237 Via De Ventura Suite 135

Scottsdale, AZ 85258

 

With a copy to:

 

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail

Raleigh, NC 27604

Attn: David Mannheim, Esq.

(919) 781-4000, wmannheim@wyrick.com

 

If to the Seller to:

 

Sun Pharmaceutical Industries, Inc.

[***]

 

or to such other Person or address as any party shall specify
by notice in writing to the other party. All such notices, requests, demands, waivers and communications shall be deemed to have been
given (a) on the date on which so hand delivered and (b) on the third Business Day following the date on which so mailed, except for a
notice of change of address, which shall be effective only upon receipt thereof.

 

8.2             
Conflict; Construction of Documents. In the event of any conflict between the provisions of this Agreement and the provisions
of any Ancillary Agreements, the provisions of this Agreement shall prevail.

 

8.3             
Assignability; Successors and Assigns. Neither this Agreement nor any of the rights or obligations of the Parties hereunder
may be assigned by any Party without the prior written consent of the other Party, provided that a Party may assign its rights and obligations
under this Agreement, without the prior written consent of the other party, to an Affiliate or to a successor of the assigning party by
reason of merger, sale of all or substantially all of its assets or any similar transaction. Any attempted assignment or delegation in
contravention hereof shall be null and void. Subject to the foregoing, this Agreement and all rights and powers granted and obligations
created hereby will bind and inure to the benefit of the Parties hereto and their respective successors and assigns.

 

8.4             
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without
regard to the conflicts of law rules of such state and subject to Section 8.5, the courts in the State of New York shall have exclusive
jurisdiction.

 

8.5              Dispute
Resolution. In the event of any dispute arising out of or in connection with this Agreement, the dispute shall be settled by
arbitration in accordance with American Arbitration Association and its rules which are deemed to be incorporated by reference to
this section, for the time being in force. The arbitral tribunal shall consist of a sole arbitrator appointed in accordance with the
said rules. The seat of arbitration shall be New York and the language of the arbitration shall be English. The award rendered by
the sole arbitrator shall be final and binding and enforceable in any court of competent jurisdiction.

 

    17

     

    

 

8.6             
Headings. The headings preceding the text of the Sections and subsections hereof are inserted solely for convenience of
reference, and shall not constitute a part of this Agreement, nor shall they affect its meaning, construction or effect. All words used
in this Agreement will be construed to be of such gender or number as the context may require.

 

8.7             
Amendment and Waiver. The Parties may by mutual written agreement amend this Agreement in any respect, and any Party, as
to such Party, may (a) extend the time for the performance of any of the obligations of any other Party, and (b) waive (i) any inaccuracies
in warranties by any other Party, (ii) compliance by any other Party with any of the agreements contained herein and performance of any
obligations by such other Party, and (iii) the fulfillment of any condition that is precedent to the performance by such Party of any
of its obligations under this Agreement. To be effective, any such amendment or waiver must be in writing and be signed by both Parties.

 

8.8             
Entire Agreement. This Agreement, together with the Ancillary Agreements, shall constitute the entire understanding and
agreement between the Parties to it in relation to the subject matter of this Agreement and shall together supersede all previous agreements
between the Parties in relation to the same subject matter. It is further agreed that neither Party has entered into this Agreement in
reliance upon any warranty or undertaking of the other Party which is not expressly set out or referred to in this Agreement.

 

8.9             
Press Release. Neither Party shall issue any press release, trade announcement or make any other public announcement with
regard to the transactions contemplated by this Agreement without the other Party’s prior written consent, which shall not be unreasonably
withheld. This restriction shall not apply to announcements required by any Government Authority. However, in such event the Parties shall,
to the extent reasonably practicable, coordinate the wording of any such announcements. To the extent any Party is required to file a
copy of this Agreement or any Ancillary Agreement as an exhibit to any filings with, or otherwise publicly disclose the terms hereof or
thereof to, the Governmental Entity, the Parties will coordinate in advance on the form of redacted version of this Agreement or applicable
Ancillary Agreement or the terms to be so filed or disclosed and permit the other Party to provide comments and take such comments into
account in good faith prior to making such filing.

 

8.10         
No Third Party Beneficiary Rights. This Agreement is not intended to and shall not be construed to give any Person or entity
other than the Parties signatory hereto any interest or rights (including, without limitation, any Third Party beneficiary rights) with
respect to or in connection with any agreement or provision contained herein or contemplated hereby.

 

8.11         
Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other
acts, as may be reasonably necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

    18

     

    

 

8.12          Severability.
Each of the agreements, undertakings, covenants, warranties, indemnities and other obligations of the Parties entered pursuant to
this Agreement are considered reasonable by the Parties hereto. If any provision of this Agreement, an Ancillary Agreement, or any
part thereof is held void or unenforceable or in conflict with the laws of any relevant jurisdiction, the Parties hereto shall
negotiate in good faith to modify this Agreement or Ancillary Agreement, as applicable, so as to effect the original intent of the
Parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as
originally contemplated to the greatest extent possible.

 

8.13         
Relationship. The relationship between the parties is that of independent contractor. Nothing in this Agreement shall be
construed as creating a relationship of a joint venture, partners, employer-employee, or agent. Neither party has the authority to create
any obligations for the other, or to bind the other to any representation or document.

 

8.14         
Counterparts. This Agreement may be executed in two counterparts, each of which shall for all purposes be deemed to be an
original and both of which shall, when taken together, constitute one instrument.

  

(Signatures appear on the
following page)

 

    19

     

    

 

IN WITNESS WHEREOF, the Parties
hereto have executed this Agreement as of the Effective Date.

 

	 	JOURNEY MEDICAL CORPORATION
	 	 
	 	 	By: 	/s/
    Claude Maraoui            
	 	 	 	Name: Claude Maraoui
	 	 	 	Title: President &CEO
	 	 
	 	SUN PHARMACEUTICAL INDUSTRIES, INC.
	 	 
	 	 	By:	 /s/ Abhay Gandhi
	 	 	 	Name: Abhay Gandhi
	 	 	 	Title: CEO — North America

 

Signature Page to Asset Purchase Agreement

 

    Page 1 of 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]